U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira^® (adalimumab)

Alvotech disclosed that under the recently announced US strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® for Quallent Pharmaceuticals, in alignment with its US commercialization agreement with Teva.